durobinet schreef op 28 augustus 2017 12:56:
Gilead to Buy Kite Pharma for Roughly $11 Billion in Cash
Drugmaker seeks to diversify portfolio as sales of its hepatitis C drugs decline
By Jonathan D. Rockoff
Aug. 28, 2017 6:33 a.m. ET
Gilead Sciences Inc. has agreed to pay about $11 billion for Kite Pharma Inc. and its promising new technology for harnessing the body’s immune system to fight cancer, according to people familiar with the matter.